 |
Net sales for the
year ending 31 March 2008, up 57%. |
|
|
29 products last year, including
tentative approvals for 8 products. |
| |
|
|
|
|
|
International markets are
now at 55% sales, further strengthening our presence as
an international pharma generic company. |
|
|
To further strengthen our capabilities as
a vertically integrated company, 31 API’s were developed,
scaled up and brought to commercial production. This confers
cost and speed to market advantages. |
| |
|
|
|
|
|
India formulations continues
to be a large part of our turnover, accounting for 43%
of our business. |
|
|
R&D for generics and API development
at 9% of net sales was amongst the sector's highest. |
| |
|
|
|
|
|
Ex- US branded generics grew
10% in value terms. |
|
|
A total of 215 patents have been have been
filed so far, of which 59 were granted. |
| |
|
|
|
|
|
Sales at our 76% subsidiary
in the US, Caraco Pharma
Labs, were up 200% for the year ending March 31, 2008. |
|
|
Employee strength is over 8000, of which
1400 are based abroad, including at our subsidiaries. |
| |
|
|
|
|
|
Between Sun Pharma and Caraco,
ANDAs for 53 products
are now approved including generic Trileptal and Protonix
where we had first-to-file exclusivity. This compares
with |
|
|
|
